Oncology Institute Return On Asset vs. Price To Sales

TOI Stock  USD 0.21  0.02  10.53%   
Based on the measurements of profitability obtained from Oncology Institute's financial statements, Oncology Institute may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Oncology Institute's ability to earn profits and add value for shareholders. The current Price To Sales Ratio is estimated to decrease to 0.44. The current Days Sales Outstanding is estimated to decrease to 34.10. As of now, Oncology Institute's Net Income Per E B T is increasing as compared to previous years.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.220.1837
Fairly Up
Slightly volatile
For Oncology Institute profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncology Institute to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncology Institute utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncology Institute's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncology Institute over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.77)
Revenue Per Share
4.873
Quarterly Revenue Growth
0.229
Return On Assets
(0.19)
Return On Equity
(1.26)
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Oncology Institute Price To Sales vs. Return On Asset Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Oncology Institute's current stock value. Our valuation model uses many indicators to compare Oncology Institute value to that of its competitors to determine the firm's financial worth.
Oncology Institute is currently regarded as top stock in return on asset category among its peers. It is rated fifth in price to sales category among its peers . As of now, Oncology Institute's Price To Sales Ratio is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncology Institute's earnings, one of the primary drivers of an investment's value.

Oncology Price To Sales vs. Return On Asset

Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Oncology Institute

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.19
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Oncology Institute

P/S

 = 

MV Per Share

Revenue Per Share

 = 
0.04 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Oncology Price To Sales Comparison

Oncology Institute is currently under evaluation in price to sales category among its peers.

Oncology Institute Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Oncology Institute, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncology Institute will eventually generate negative long term returns. The profitability progress is the general direction of Oncology Institute's change in net profit over the period of time. It can combine multiple indicators of Oncology Institute, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Interest Income-7.3 M-6.9 M
Operating Income-77 M-73.2 M
Net Loss-75.3 M-71.6 M
Income Before Tax-83.1 M-78.9 M
Total Other Income Expense Net-6.1 M-5.8 M
Net Income Applicable To Common Shares61.2 K64.3 K
Net Loss-83.1 M-78.9 M
Income Tax Expense-36 K-34.2 K
Non Operating Income Net Other98.8 M103.8 M
Change To Netincome-42.5 M-40.4 M
Net Loss(1.13)(1.07)
Income Quality 0.44  0.46 
Net Income Per E B T 1.00  1.12 

Oncology Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Oncology Institute. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncology Institute position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncology Institute's important profitability drivers and their relationship over time.

Use Oncology Institute in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncology Institute position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncology Institute will appreciate offsetting losses from the drop in the long position's value.

Oncology Institute Pair Trading

Oncology Institute Pair Trading Analysis

The ability to find closely correlated positions to Oncology Institute could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncology Institute when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncology Institute - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncology Institute to buy it.
The correlation of Oncology Institute is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncology Institute moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncology Institute moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncology Institute can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Oncology Institute position

In addition to having Oncology Institute in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tech Funds Thematic Idea Now

Tech Funds
Tech Funds Theme
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:
Check out World Market Map.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
To fully project Oncology Institute's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Oncology Institute at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Oncology Institute's income statement, its balance sheet, and the statement of cash flows.
Potential Oncology Institute investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Oncology Institute investors may work on each financial statement separately, they are all related. The changes in Oncology Institute's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Oncology Institute's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.